The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

GlaxoSmithKline, DualityBio, Latin American Cooperative Oncology Group, Mirati Therapeutics Inc., Eli Lilly and Company, Fox Chase Cancer Center, Merck Sharp & Dohme LLC, BeiGene, NeoImmuneTech ...

GSK'227 targets B7-H3 ... Arexvy and Shingrix as well as a one-off credit from the Zejula royalty dispute in quarter 1. R&D grew 7%, broadly in line with sales as we invested in Phase 3 trials ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...

GSK plc GSK reported fourth-quarter 2024 core ... it received approval in the EU in January 2024. Zejula sales fell 3% in the quarter. Though the drug’s U.S. sales were adversely impacted ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. Last quarter, its operating ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines. The University of Oxford and GSK are to work on a vaccine to target cells in the ...

For instance, GSK reported in March 2024 that Zejula (niraparib) had received FDA approval as a first-line maintenance treatment for advanced ovarian cancer. By type, the epithelial tumors segment ...